ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2022
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.Annals of surgical oncology · 2025Trial
- Optical Tissue Clearing and Small-Molecule Labeling of Paraffin-Embedded Breast Cancer and Axillary Lymph Node Human Tissue Samples.Bio-protocol · 2026Article
- Oncological Outcomes of Breast-Conserving Surgery Versus Mastectomy in Invasive Lobular Breast Cancer: A Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Article
- Frequency and survival of delayed breast cancer diagnosis in women participating at screening mammography in the Netherlands: a population-based study.The Lancet regional health. Europe · 2026Article
- Lobular breast cancer and prognosis: what should we tell patients?Frontiers in oncology · 2026Review
- Molecular and Biological Features of Invasive Lobular Carcinoma: Toward New Treatment Strategies.Annals of surgical oncology · 2026Review
- The association between parity, age of first full term pregnancy and invasive lobular breast cancer: a case-only analysis.Cancer treatment and research communications · 2026Article
- The Canadian Breast Cancer Symposium 2025: Meeting Report.Current oncology (Toronto, Ont.) · 2025Article
- Pitfalls in the Histological Diagnosis of Morphologic Variants of Invasive Lobular Carcinoma of the Breast.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Review
- Exploring the Microbiome in Breast Cancer: The Role ofMicroorganisms · 2025Review
- Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study.Breast cancer research : BCR · 2025Article
- Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review).International journal of oncology · 2025Review
- A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.NPJ breast cancer · 2025Article
- Review
- Recent advances and updated highlights in breast cancer pathologic diagnosis: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Comprehensive characterization of invasive mammary carcinoma with lobular features: integrating morphology and E-cadherin immunohistochemistry patterns.Breast cancer (Tokyo, Japan) · 2025Article
- Fusing global context with multiscale context for enhanced breast cancer classification.Scientific reports · 2024Article
- A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms.Cancer research · 2024Article
- Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer.Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive lobular carcinoma (ILC) represents the second most common subtype of breast cancer (BC), accounting for up to 15% of all invasive BC. Loss of cell adhesion due to functional inactivation of E-cadherin is the hallmark of ILC. Although the current world health organization (WHO) classification for diagnosing ILC requires the recognition of the dispersed or linear non-cohesive growth pattern, it is not mandatory to demonstrate E-cadherin loss by immunohistochemistry (IHC). Recent results of central pathology review of two large randomized clinical trials have demonstrated relative overdiagnosis of ILC, as only ~60% of the locally diagnosed ILCs were confirmed by central pathology. To understand the possible underlying reasons of this discrepancy, we undertook a worldwide survey on the current practice of diagnosing BC as ILC. A survey was drafted by a panel of pathologists and researchers from the European lobular breast cancer consortium (ELBCC) using the online tool SurveyMonkey®. Various parameters such as indications for IHC staining, IHC clones, and IHC staining procedures were questioned. Finally, systematic reporting of non-classical ILC variants were also interrogated. This survey was sent out to pathologists worldwide and circulated from December 14, 2020 until July, 1 2021. The results demonstrate that approximately half of the institutions use E-cadherin expression loss by IHC as an ancillary test to diagnose ILC and that there is a great variability in immunostaining protocols. This might cause different staining results and discordant interpretations. As ILC-specific therapeutic and diagnostic avenues are currently explored in the context of clinical trials, it is of importance to improve standardization of histopathologic diagnosis of ILC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.